NRX Pharmaceuticals Inc (NRXP)
2.10
+0.04
(+1.94%)
USD |
NASDAQ |
May 03, 16:00
2.01
-0.09
(-4.29%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 20.10M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -64.79% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.63% |
Profile
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
URL | https://nrxpharma.com |
Investor Relations URL | https://ir.nrxpharma.com/ |
HQ State/Province | Delaware |
Sector | |
Industry | |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 16, 2024 (est.) |
Last Earnings Release | Apr. 01, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
URL | https://nrxpharma.com |
Investor Relations URL | https://ir.nrxpharma.com/ |
HQ State/Province | Delaware |
Sector | |
Industry | |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 16, 2024 (est.) |
Last Earnings Release | Apr. 01, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |